entertainment -WSS

entertainment

author：comprehensive 2025-09-28 00:53:54 - browse：453

FDA stop sign — Sarah Silbiger/Getty Images

The Food and Drug Administration is cracking down on websites that claim to sell the underlying chemicals of popular diabetes and obesity drugs like Ozempic, Wegovy, and Zepbound, saying that the websites are selling unapproved and misbranded drug products.

The regulator this week posted warning letters that it sent to two websites, Synthetix Inc. DBA Helix Chemical Supply and US Chem Labs. Though those websites say their chemicals are “for research use” and “not for human consumption,” the FDA said it found evidence on their pages showing that their products are indeed intended for human use, such as information about dosing and claims about the clinical benefits of the products.

The two websites did not immediately respond to requests for comment. The FDA said they have 15 working days to respond and detail the steps they’ve taken to address any violations.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Asbestos, a deadly carcinogen, banned by EPA

WSS

Opioid cravings were reduced by anti

Opioid cravings were reduced by anti

Stop the failed accountable care organization experiment

U.K. researchers warn about biases in medical devices, algorithms

Creating egg and sperm cells from stem cells raises ethical issues

New study raises questions about niacin and heart health

focus

entertainment

Wikipedia

What does generative AI mean for health care? We asked experts

Measles policy set amid Florida outbreak alarms vaccine proponents

ChatGPT in medicine: STAT answers readers' burning questions

Flagship Pioneering startup Sonata Therapeutics lays off 21

Hepatitis C has a cure — but many Americans still lack access to it

Reporting on presidential health from Reagan to Trump and Biden

Virginia high school admissions case could be legal follow

Elevance, SCAN deals highlight health insurer acquisition scrutiny

DIEP, the 'gold standard' of breast reconstruction, is under threat

Asbestos, a deadly carcinogen, banned by EPA

leisure time

AstraZeneca to buy developer of next

Elevance, SCAN deals highlight health insurer acquisition scrutiny

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

Abridge raises $150m as clinical notes automation market heats up

Neuroscience’s long legacy of racism

Gene editing the human germline: What are the risks?

knowledge

explore

focus

entertainment